ES8R
TEAS SECTION 8 RECEIVED
08/07/2026
Voltar para busca
Dado oficial do USPTO
3D TUMORSPHERE MEDIUM
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
3D TUMORSPHERE MEDIUM
ST13
US500000088382241Classe
1, 5, 10
Pedido
88382241
Registro
6143842
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
28
Atualização mais recente
09/07/2026
Tipo de marca
Verbal
Classes Nice
1, 5, 10
Data de depósito
11/04/2019
Data de registro
01/09/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/09/2020
Última transação
09/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Supplemental Register
Código do desenho
4
Tipo de titular
27
Localização do titular
HEIDELBERG, DE
Examinador
SHINN, LAUREN DONGMI
Unidade examinadora
O10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
PROMOCELL GMBH
PromoCell bioscience alive GmbH Biomedizinische Produkte
Representantes
Shoko Naruo Thompson Coburn LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
basesraw materialsauxiliaries and active ingredientsall being types of chemicals for use in industry and science for producing chemicalbiochemicalbiological and cell biological preparations; media for cell culture for use in the biotechnological industry and for non-medical research laboratories; biological preparation for use in cell cultures other than for medical or veterinary use; chemical products used in industrychemicals for use in in vitro research and development applications; biochemicals used in industryin in vitro research and development applications; biological preparations for use in industry; cytobiological preparations for use in industry; base materialsraw materialsauxiliary materials and active substancesall being types of chemicals for use in manufacturing biomedical and medical preparations
Classe 5
medicines for regenerative purposescancercardio vascular diseasesrespiratory diseasesdermatological diseases; pharmaceutical preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; sanitary preparations for medical use; dietetic foodstuffs adapted for medical use; foodstuff supplements adapted for medical use; plasters for medical use and bandageswadding and gauze for dressings; chemicalbiochemicalbiologicalcellular biological preparations for medical and biomedical science purposescell and stem cell applicationsregenerative solutions and for the treatment of cancerdermatological diseasesrespiratory diseasescardio vascular diseases; cell cultures for cultivating human and animal cellsfor medical purposes
Classe 10
cell culture systems for medical usecell culture chambers used for human and animal cells
Publicações
Histórico de despachos e eventos da marca no USPTO.
28 publicações encontradas
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/09/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
24/03/2021
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
01/09/2020
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
28/07/2020
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
22/07/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
22/07/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
22/07/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
22/07/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
22/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/07/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
09/07/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
29/01/2020
GNFR
FINAL REFUSAL E-MAILED
29/01/2020
CNFR
FINAL REFUSAL WRITTEN
29/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/12/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
26/06/2019
GNRT
NON-FINAL ACTION E-MAILED
26/06/2019
CNRT
NON-FINAL ACTION WRITTEN
26/06/2019
DOCK
ASSIGNED TO EXAMINER
20/06/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
30/05/2019
ALIE
ASSIGNED TO LIE
30/05/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
24/05/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
29/04/2019
NWAP
NEW APPLICATION ENTERED
15/04/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace 3D TUMORSPHERE MEDIUM ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.